American Century Companies’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

American Century Companies’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-39,589	Closed	-$751K	–	1388
2015 Q4	$751K	Buy	+39,589	New	+$860K	﹤0.01%	1146

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

American Century Companies's CNCE Position: Q1 2016 in Review

American Century Companies sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2016, closing a stake of 39,589 shares — an estimated $751K sold.

American Century Companies first reported a position in CNCE in Q4 2015 and held it in 1 quarter. The position peaked at $751K in Q4 2015. 97 funds tracked by Wall St. Rank hold CNCE as of Q1 2016.

American Century Companies reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
American Century Companies sold 39,589 Concert Pharmaceuticals, Inc. shares in Q1 2016, an estimated $751K.
American Century Companies first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
American Century Companies's Concert Pharmaceuticals, Inc. position peaked at $751K in Q4 2015.
97 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2016.

Based on American Century Companies's 13F filing for Q1 2016, filed 2 May 2016.